(Q73523464)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

C Pichoud

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

F Berby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Stuyver

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M A Petit

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C Trépo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 February 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

307-316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus infection

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Chronic type B hepatitis and the "healthy" HBsAg carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Naturally occurring variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Long-term follow-up of anti-HBe-positive chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Comparison of methods for detection of hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Comparison of four methods for quantitative measurement of hepatitis B viral DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980077-X

7 January 2021

10.1016/S0168-8278(00)80077-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10707872%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference